WA received speaking honoraria from Roche, Medscape, Aptitude Health, Clinical Education Alliance, OncLive/MJH Life Sciences, and touchIME; consulting fees from Clovis Oncology, Janssen, ORIC Pharmaceuticals, Daiichi Sankyo, and AstraZeneca; and royalties from UptoDate and research funding to his institution from AstraZeneca, Zenith Epigenetics, Clovis Oncology, ORIC Pharmaceuticals, and Epizyme. Some of the consulting activities, speaking honoraria, and research funding are related to PARP inhibitor use in prostate cancer. WA receives research funding from the National Cancer Institute (NCI) Cancer Center Support grant number P30-CA008748, NCI Prostate Specialized Program of Research Excellence (SPORE) grant number P50-CA092629-16, and the Prostate Cancer Foundation. GA is on the steering committees of the MAGNITUDE and AMPLITUDE trials sponsored by Janssen and is a Principal Investigator of clinical trials sponsored by Janssen, Pfizer (PROSPER, NCT02003924), and Novartis. GA has received consulting fees from Janssen, Pfizer, AstraZeneca, and Clovis and speaker fees from AstraZeneca and Janssen to speak on prostate cancer, including regarding PARP inhibitors. GA has participated in advisory boards for Janssen, Pfizer, Astra Zeneca, and Clovis on topics related to prostate cancer, including PARP inhibition. GA has received research grants to their institution from Janssen, Astellas, and Novartis for subjects related to prostate cancer. GA has also received consulting fees from Novartis, Bayer, Blue Earth Therapeutics, Boehringer, and Roche, which are companies with drugs in development for prostate cancer; and receives a share of the royalty income from The Institute of Cancer Research Rewards to Discoverers Scheme for abiraterone as personal royalties. GA holds a patent on plasma methylation signatures as biomarkers for prostate cancer (GB1915469.9). This patent is held by funders (Cancer Research UK). GA is listed as an inventor and could receive a share of commercial revenue via their institution University College London. This patent is not related to this study or PARP inhibitors but is a blood test that is being developed for the diagnosis or risk stratification of prostate cancer.